veliparib (ABT-888)

DRUG4 trials

Sponsors

AbbVie (prior sponsor, Abbott), AbbVie

Conditions

Advanced Solid TumorsBreast CancerColon CancerGastric CancerLung CancerOvarian CancerSolid Tumors

Phase 1

A Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors

CompletedNCT01063816

AbbVie (prior sponsor, Abbott)Advanced Solid Tumors

Start: 2010-01-31End: 2016-08-31Updated: 2021-08-02

A Study of Veliparib in Combination With Carboplatin and Paclitaxel in Japanese Subjects With Solid Tumors

CompletedNCT01617928

AbbVie (prior sponsor, Abbott)Solid Tumors

Start: 2012-05-31End: 2013-07-31Updated: 2017-11-20

A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors

CompletedNCT02009631

AbbVieBreast Cancer, Colon Cancer, Gastric Cancer +3

Start: 2013-11-30End: 2014-12-31Updated: 2017-11-20

A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors

CompletedNCT02210663

AbbVieAdvanced Solid Tumors

Start: 2014-07-31End: 2016-07-31Updated: 2018-05-07

Related Papers

Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.

2018-01-1749 citations

Phase 1 dose‐escalation study of single‐agent veliparib in Japanese patients with advanced solid tumors

Cancer Science2017-06-3024 citations

Abstract CT149: Assessment of the cardiac safety of veliparib in a thorough QT/QTc study at therapeutic doses in patients with relapsed/refractory solid tumors: a randomized, placebo-controlled crossover study

Cancer Research2016-07-151 citations